Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ ...
Frontiers7d
New molecular targets for personalized treatment for Low-Grade Non-Hodgkin Lymphoma
Recent years have witnessed notable progress in tailoring treatments for solid tumors using biomarkers. Nevertheless, identifying specific biomarkers for ...
C&EN26d
Cannabidiol Targets Colorectal Cancer Cells via Cannabinoid Receptor 2, Independent of Common Mutations
School of Pharmacy, The University of Queensland, Brisbane 4102, Australia Inflammatory Bowel Diseases Group, Mater Research Institute─UQ at Translational Research Institute, The University of ...